HCV PROJECT PUBLICATIONS
1st Hepatitis C Virus World Community Advisory Board Report
July 14, 2014 — The hepatitis C virus (HCV) World Community Advisory Board (CAB) grew from an international AIDS activist movement. The objectives of the meeting were three-fold: 1. To provide a forum for leading activists to learn about developments in HCV treatment and access barriers; 2. To find common advocacy strategies; and 3. To meet with pharmaceutical companies about their plans for low- and middle-income countries (LMICs).
Defuse Hepatitis C, the Viral Time Bomb: Test and Treat Hepatitis C
Position Paper for the 67th World Health Assembly, May 19–24, 2014
We, people living with HCV, HIV/AIDS, people who use drugs, and our advocates, urge United Nations (UN) Member States to act with urgency to end the hepatitis C epidemic; it is possible!
TRAINING MANUAL FOR TREATMENT ADVOCATES: Hepatitis C Virus and Coinfection with HIV
November 2013 – The information here is written by and for people who are not medical specialists. We are treatment activists who learned about hepatitis C because it was a problem for people in our communities. We designed it to help you understand basic information about hepatitis C and coinfection with HIV: how it is transmitted, how to prevent hepatitis C, how a person can find out if he or she has hepatitis C, what happens to both HIV-negative and HIV-positive people who have hepatitis C, information used for making treatment decisions, and treatment options.
Hepatitis C and the IL28B Gene Fact Sheet
April 2013 – This fact sheet describes how the genetic factor IL28B affects responses to hepatitis C treatment, including poorer efficacy among African Americans and people of African ancestry.
Updated HCV Protease Inhibitor Fact Sheets in English and Spanish
April 2013 – These fact sheets describe how each drug should be used, how likely treatment is to be successful, common side effects, drugs that cannot be used with each HCV protease inhibitor, and information about co-pay assistance and patient assistance programs.
Guide to Clinical Trials for People with Hepatitis C (Second Edition)
January 2013 – There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated. Having more information can help you decide whether or not to participate in a clinical trial, and which trial, or trials, may be right for you. This guide is available in English and Spanish.
HCV Treatment Pipeline Update
December 12, 2012 – It is difficult to be anything other than dazzled by astounding cure rates of up to 100% from a multitude of interferon-free hepatitis C virus (HCV) clinical trials presented at the American Association for the Study of Liver Diseases (AASLD) meeting in November 2012. Proof of concept has been established: hepatitis C, a disease that claims more than 350,000 lives annually, can be cured with three months of oral antiviral drugs.
2012 Pipeline Report
HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development
July 22, 2012 – Visit our new website www.PipelineReport.org to:
- Read the report online
- Download individual chapters as PDFs
- Browse for specific information by agent
What You Don’t Know, You Can Sell: Merck’s Cavalier Attitude Toward the Welfare of HIV/HCV-Coinfected Patients
TAGline Spring 2012 – In places where access to antiretroviral therapy is widespread, people living with HIV are now dying from a common and curable coinfection: hepatitis C virus (HCV). HIV increases the risk for, and accelerates the rate of, liver disease from hepatitis C. Pegylated interferon and ribavirin, medications used to treat HCV, are less effective in people with HIV than in their HCV-monoinfected counterparts. In 2011, the first hepatitis C protease inhibitors, Merck’s boceprevir and Vertex’s telaprevir, were approved based on trials in people with hepatitis C monoinfection. Both drugs are being studied in coinfected people, thanks to pressure from the international HIV/HCV community and encouragement from regulatory agencies.
HCAB Position Statement: Hepatitis C Drug Development and Drug-Drug Interaction Studies
February 2012 – The Hepatitis C Community Advisory Board (HCAB) recognizes the value of more effective and less toxic treatment for hepatitis C virus (HCV). We believe that sponsors can conduct key drug-drug interaction (DDI) studies with direct-acting antivirals (DAAs) and other candidates in development and medications commonly used by people with hepatitis C and those coinfected with HIV/HCV prior to their approval, without delaying development of these important therapies.
2011 Pipeline Report (Second Edition)
September 2011 – HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development
The Hepatitis C Treatment Pipeline Report
March 2011 – Interferon is the therapeutic backbone of hepatitis C virus (HCV) treatment, as well as the major barrier to HCV treatment access, uptake, and completion. For many people, hepatitis C treatment does not work, and side effects can be debilitating. Fortunately, scientific advances and keen interest from the pharmaceutical industry have led to the development of dozens of new oral antiviral drugs for hepatitis C. Hopefully, it will soon be possible to replace interferon with a combination of HCVspecific oral drugs (commonly referred to as direct-acting antivirals, or DAAs) that will work for everyone.
Access to Hepatitis C Treatment: A Global Movement Gains Momentum
TAGline Fall 2010 - For several years, a few activists have been pushing for global access to treatment for HCV. Although HCV treatment remains unaffordable, momentum for global access to such treatment is building.
2010 Pipeline Report (Second Edition)
HIV, Tuberculosis, and Viral Hepatitis: Drugs, Diagnostics, Vaccines, Immune-Based Therapies, and Preventive Technologies in Development
September 2010 - This year TAG collaborated with HIV i-Base UK. Simon Collins contributed an in-depth analysis of the Antiretroviral Pipeline and Polly Clayden wrote new chapters for the report on Pediatric Antiretrovirals and HIV diagnostics. The second edition includes information from the XVIII International IAS Conference in Vienna, Austria, July 2010.
Do the Right Thing: Eliminating Racial Disparities in Viral Hepatitis Drug Development
December 2009 – In the United States, the highest all-cause mortality rates are found among African American men and women aged 25 to 64. This racial disparity is underscored by a disproportionate burden of viral hepatitis among African Americans; hepatitis B virus (HBV) is 4.6 times more prevalent, and hepatitis C virus (HCV) is twice as prevalent among African Americans than Caucasians.
Guide to Hepatitis C for People Living with HIV - Testing, Coinfection, Treatment, and Support
October 2009 Welcome to our treatment guide for HIV-positive people who also have the hepatitis C virus (called HCV, for short). The people who wrote this guide have direct experience with HIV and hepatitis C. We have written this guide to encourage you to explore the range of care and treatment choices available to you. We hope this information helps you feel more in control of some of your HCV treatment choices, so that you can focus on other things you want to do in life.
Guide to Hepatitis B for People Living with HIV
June 2009 – Welcome to this treatment guide for HIV-positive people who also have hepatitis B (HBV). This guide provides information on the prevention, care, and treatment of HBV, and the impact of HBV on HIV disease. It is designed to be accessible to people with no medical training. Where medical terms are used, they are explained in detailed but simple language.
2009 Pipeline Report
HIV, Tuberculosis, and Viral Hepatitis: Drugs, Diagnostics, Vaccines, and Microbicides in Development
July 2009 – The Pipeline Report is TAG's annual survey of the developments in medicines and diagnostics most likely to improve the lives of people living with HIV, viral hepatitis, and tuberculosis within the next few years. But in spotlighting what is in the pipeline, the report also identifies critical gaps where research is falling short of the need for better tools to manage these diseases.
State AIDS Drug Assistance Program (ADAP) Hepatitis Coverage
TAGline June 2009 – Hepatitis C Treatment, Psychiatric Medications (SSRIs), Growth Factors, Hepatitis Vaccines (March 2009)
New Hepatitis C Epidemic Outbreaks in HIV-Positive Gay Men
TAGline April 2009 – Outbreaks of sexually transmitted hepatitis C infection have been reported among HIV-positive gay men. Early diagnosis and treatment can prevent serious liver disease, but too few doctors notice the warning signs.
A Delicate Balance: Accelerated Approval and Postmarketing Commitments
TAGline April 2009 – Research presentation poster by Tracy Swan and Lei Chou; winner of a Chairman’s Choice Award at the 2008 HIV DART conference “Frontiers in Drug Development for Antiretroviral Therapies.”
2008 Pipeline Report
HIV, Tuberculosis, Hepatitis B, and Hepatitis C: Drugs, Diagnostics, Vaccines, and Microbicides in Development
July 2008 – The Pipeline Report is Treatment Action Group’s annual review of medical technologies that stand a good chance of benefiting people with HIV within the next few years. It also covers those that may take longer to develop but represent innovation within the field.
Hepatitis C: New Treatments in the Pipeline
April 2008 – Hepatitis C virus (HCV) is a serious global health problem. According to the World Health Organization (WHO), which describes HCV as a “viral time bomb,” 130 million people have chronic hepatitis C, and 3 to 4 million more become infected each year. If untreated, or unresponsive to treatment, chronic HCV leads to cirrhosis in 20–30% of people. Each year, ~4% of people with hepatitis C–associated cirrhosis develop liver cancer, and ~6% will experience liver failure. The WHO estimates that up to 75% of liver cancer and ~65% of liver transplants occurring in the developed world are attributable to chronic HCV infection.
2007 Pipeline Report: Experimental Treatments and Preventive Therapies for HIV, Hepatitis C, and Tuberculosis
July 2007 – The Pipeline Report is Treatment Action Group’s annual review of experimental technologies that have the potential to solve critical unmet medical needs surrounding HIV infection and AIDS.
Access to Hepatitis C Treatment Through State AIDS Drug Assistance Programs (ADAPs)
May 31, 2007 – Access to hepatitis C treatment is crucial for HIV/HCV-coinfected people. Although hepatitis C can be treated, HCV-associated end-stage liver disease has become a leading cause of death among HIV-positive people in the United States.
2006 Pipeline Report
New HIV Drugs, Vaccines, Microbicides, HCV and TB Therapies in Clinical Trials
August 2006 – TAG’s 2006 Pipeline Report focuses on a key part of the product development pipeline for biomedical interventions to prevent or treat HIV and its two most common deadly global coinfections: tuberculosis (TB) and hepatitis C virus (HCV) infection.
2005 Pipeline Report
New HIV Drugs, Vaccines, Microbicides, HCV and TB Treatments in Clinical Trials
July 2005 – This overview of the antiretroviral, vaccine, microbicide, immune-based therapy, and anti-HCV and TB drug pipeline (focusing on products that have advanced to clinical testing in humans) reveals the state of research on AIDS and its most common global coinfections in mid-2005. The news is mixed.
Hepatitis C Virus (HCV) and HIV/HCV Coinfection: A Critical Review of Research and Treatment
July 2004 – TAG’s hepatitis C and HIV/HCV coinfection report is a comprehensive review of basic and clinical science accompanied by recommendations for research and policy. It was written for people living with hepatitis C or HIV/HCV coinfection, clinicians, researchers, activists, educators, and advocates.
Chronic Shortage of Donor Organs Threatens People with HIV, 2004
Regardless of HIV Status, Transplant Candidates Face a Daunting Shortage of Livers
TAG's HCV/HIV Coinfection Project Director, Tracy Swan, explores the impact of the chronic organ shortage on HIV-positive people who have developed end-stage liver disease (ESLD) from coinfection with viral hepatitis (and other causes), and ideas to increase the supply of donor organs.
For older publications, please go to the publications page.